Traditional ways to screen new product innovation opportunities includes effort/benefit analysis, cost/margin analysis, or risk/attractiveness matrices. A different method to screen these opportunities is to pay close attention to the expected differential economic value they generate versus... Read More

One of the things we recognize as we work with customers about to undertake this kind of initiative is that it can be daunting. There is a lot to do. Further, the work can be risky from a personal as well as professional standpoint. It would be great if we could just show up, deliver and implement... Read More

I was looking for more information on how well ideation processes work this week, and I came across a great study by Karan Girotra, Christian Terwiesch, and Karl T. Ulrich at University of Pennsylvania was called “Idea Generation and the Quality of the Best Idea”. They ran a clever experiment to... Read More

For innovation initiatives to have the most impact, they must be tied to the strategic objectives of the company. Too often, I've seen R&D managers working in the dark, not knowing what is important to the company or to the customer. If R&D managers don't know their company's priorities, they can't... Read More

Editor's note: This is the first in a series of three blog posts over the coming weeks. Read More

Editor's note: This is the second in a series of three blog posts. Read More

Editor's note: This is the first in a series of three blog posts. Read More

People often ask me about the innovation, new product development, and portfolio management trends I'm seeing in the field. For many years, I saw that companies' first priority was to automate the gated development process. That is, companies needed to automate the process of moving new products... Read More

Innovation is often used when discussing software applications. There are many applications that support or somehow play a role in innovation and yet there are sometimes puzzled looks and misunderstandings when the term innovation is used. One person's view of innovation can be very different than... Read More

Pfizer and the NIH have taken sides on who owns background intellectual property (IP) rights to the blockbuster arthritis drug Xeljanz. Its undisputed that Pfizer invested over $1B in the drug, and its undisputed that Pfizer and NIH had an joint R&D contract, called a CRADA, in place during the... Read More